{"filings":[{"id":1360400,"accession_number":"0001104659-26-079323","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K/A","filed_at":"2026-06-30T20:05:46+00:00","items":["9.01"],"status":"ready","headline":"Collegium closes $655.6M acquisition of AZSTARYS; Corium had going concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired AZSTARYS (ADHD treatment) for ~$655.6M cash, funded by $355.6M cash on hand and $300M delayed draw term loan.","Up to $135M in additional milestone payments if AZSTARYS achieves certain commercial and manufacturing targets.","Corium's audited FY2025 net loss was $42.4M; accumulated deficit $736M; auditors flagged substantial doubt about going concern.","Corium FY2025 product sales $113.6M, up from $79.6M in FY2024; operating loss improved to $14.7M from $127.2M.","Pro forma financials filed; ADLARITY (Alzheimer's product) excluded as not part of acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470917,"accession_number":"0001104659-26-062536","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2026-05-15T20:10:34+00:00","items":["5.07"],"status":"ready","headline":"Collegium shareholders elect all eight director nominees, approve say-on-pay, ratify Deloitte","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with 25.9M to 27.4M votes for each; broker non-votes 1.79M.","Advisory vote on executive compensation approved: 26.3M for, 1.1M against, 5.6K abstentions.","Ratification of Deloitte & Touche as auditor for FY 2026 passed: 28.95M for, 252.8K against.","Meeting held May 14, 2026; 29.2M of 32.4M shares present in person or by proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22561,"accession_number":"0001104659-26-059018","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2026-05-12T11:43:29+00:00","items":["2.01","5.02","7.01","9.01"],"status":"ready","headline":"Collegium completes $650M acquisition of AZSTARYS; raises 2026 guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired AZSTARYS from Corium Therapeutics for ~$650M cash; up to $135M in commercial/mfg milestones.","Funded by $350M existing cash and $300M delayed draw term loan from Dec 2025 credit facility.","2026 guidance raised: product revenues $865M-$895M; Adj. EBITDA $475M-$500M; AZSTARYS seen at $60M-$70M remainder of year.","CCO Scott Dreyer departs Aug 30, 2026; CMO Thomas Smith departs after transition period; both treated as termination without cause.","Annual run-rate synergies expected >$50M within 12 months; AZSTARYS has patent protection through Dec 2037."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91836,"accession_number":"0001628280-26-031694","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q1 revenue up 9% to $193.5M; JORNAY PM +36%; FY guidance reaffirmed; AZSTARYS deal on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product net revenue of $193.5M (+9% YoY); GAAP diluted EPS $0.40; adjusted EPS $1.76.","JORNAY PM net revenue $38.9M (+36% YoY); prescriptions rose 14% to >206,000.","Pain portfolio net revenue $154.6M (+4% YoY); Belbuca $52.6M, Xtampza ER $50.8M.","Reaffirmed FY 2026 guidance: product revenue $805-825M, adjusted EBITDA $455-475M.","Acquisition of AZSTARYS for $650M cash on track to close Q2 2026; $135M milestone potential."],"consensus_eps_estimate":1.6232,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":193520000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91835,"accession_number":"0001628280-26-024061","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Collegium nominates Michael Donovan for board; director John Fallon to retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Donovan, 60, audit partner at EY since 2002, nominated to stand for election at 2026 annual meeting.","John Fallon, M.D., will not stand for re-election and will retire from the board effective as of the annual meeting.","Dr. Fallon served as director since 2016; his retirement is part of board refreshment and succession planning, not due to any disagreement.","Mr. Donovan brings financial expertise from 36 years of experience in life sciences audits and transactions (IPOs, M&A, collaborations)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102192,"accession_number":"0001104659-26-032166","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Collegium to acquire AZSTARYS for $650M cash; expected to close Q2 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of AZSTARYS (ADHD treatment) for $650M cash, plus up to $135M in commercial and regulatory milestones.","Funding from cash on hand and a $300M delayed draw term loan at SOFR + 3.25% interest rate.","AZSTARYS expected to generate over $50M in second half 2026 pro forma net revenue.","Transaction expected to be immediately accretive to adjusted EBITDA; net leverage ~2x as of closing.","Patent protection into 2037; closing expected Q2 2026 subject to HSR and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102191,"accession_number":"0001628280-26-011990","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q4 net rev $205.4M (+13% YoY); FY 2025 rev $780.6M (+24%); reaffirms 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $0.46 vs $0.36 YoY; adjusted diluted EPS $2.04 vs $1.77.","Jornay PM Q4 net revenue $45.9M (+57%); full-year $148.9M (+48%).","Pain portfolio FY 2025 net revenue $631.7M (+6%); Belbuca $221.7M (+5%).","Full-year adjusted EBITDA $460.5M (+15%); cash & marketable securities $386.7M.","Closed $980M credit facility in Dec; repurchased $25M shares in 2025."],"consensus_eps_estimate":2.3742,"consensus_eps_actual":1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":780567000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102190,"accession_number":"0001104659-26-001953","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Collegium Pharma guides FY2026 revenue $805-825M; Jornay PM $190-200M; adj. EBITDA $455-475M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Product revenue guidance $805-825M; Jornay PM net revenue $190-200M.","Adjusted EBITDA guidance $455-475M, flat versus raised 2025 midpoint.","Closed $980M syndicated credit facility; repaid $581M Pharmakon term loan, expects annualized interest savings.","Signed supply/quality agreements with Hikma for authorized generics of Nucynta/Nucynta ER; AG Nucynta ER launch expected Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118511,"accession_number":"0001104659-25-125026","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","1.02","3.02","7.01","9.01"],"status":"ready","headline":"Collegium closes $980M syndicated credit facility, repays Pharmakon loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$980M total facility: $580M term loan, $300M delayed draw, $100M revolver; matures 2030.","Initial term loan used to repay ~$581M of existing Pharmakon debt; previous facility was $646M.","Interest rate SOFR + 2.75%–3.75% (initial 2.75%), expected to deliver meaningful annualized interest savings.","Delayed draw and revolver undrawn at close; earmarked for general corporate purposes and M&A.","Truist Bank administrative agent; bank syndicate includes Citizens, MUFG, Fifth Third, Huntington, U.S. Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118510,"accession_number":"0001104659-25-107389","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q3 revenue $209.4M (+31% YoY); raises 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $31.5M ($0.84 diluted EPS); adj. net income $87.3M ($2.25 adj. EPS).","Record Jornay PM revenue $41.8M; prescriptions up 20% YoY; pain portfolio $167.6M (+11%).","Full-year 2025 revenue guidance raised to $775-785M; adj. EBITDA guidance $460-470M.","Ended Q3 with $285.9M cash; Board authorized $150M share repurchase through Dec 2026.","Adjusted EBITDA $133.0M, up 27% YoY; generated $78.4M cash from operations."],"consensus_eps_estimate":2.0849,"consensus_eps_actual":1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":575118000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134968,"accession_number":"0001558370-25-010647","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q2 revenue $188M (+29% YoY); raises 2025 guidance; authorizes $150M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly product revenue $188.0M, up 29% YoY; GAAP EPS $0.34 diluted; adjusted EPS $1.68.","Jornay PM net revenue $32.6M, prescriptions up 23% YoY; full-year Jornay PM guidance raised to $140-145M.","Pain portfolio revenue $155.4M (+7% YoY) with Belbuca $52.6M, Xtampza $52.6M, Nucynta $46.4M.","Raised FY2025 revenue guidance to $745-760M and adjusted EBITDA to $440-455M; cash $222.2M.","Board authorized $150M share repurchase through Dec 2026; completed $25M ASR in July."],"consensus_eps_estimate":1.649,"consensus_eps_actual":0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":365757000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134967,"accession_number":"0001104659-25-065981","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Collegium Pharmaceutical authorizes up to $150M share repurchase program through Dec 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized $150M share repurchase program, valid through Dec 31, 2026.","Repurchases will be executed on open market based on market conditions and share price.","Program funded by existing cash on hand; timing and amount of purchases discretionary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151913,"accession_number":"0001104659-25-050435","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 2025 Equity Incentive Plan authorizing 3.47M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted 20.3M for, 7.1M against to approve the 2025 Equity Incentive Plan.","Plan authorizes 3,474,404 shares for issuance to employees, directors, and consultants.","All eight director nominees elected; say-on-pay and auditor ratification also approved.","Director compensation capped at $750k annually ($1M first year).","Vesting minimum of one year for awards, except up to 5% of shares can have shorter vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151912,"accession_number":"0001104659-25-047040","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Collegium enters $25M accelerated share repurchase; 692,281 shares initially delivered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ASR with Jefferies for $25M; part of $150M repurchase program authorized Jan 2024.","Initial delivery of 692,281 shares (approx 80% of expected) at $28.89 closing price on May 9.","Final settlement expected by Q3 2025; shares based on volume-weighted average price.","As of March 31, 2025, Collegium had ~32.1M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151911,"accession_number":"0001558370-25-006957","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q1 revenue up 23% to $177.8M; guides FY25 $735-750M; authorizes $25M ASR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $177.8M (+23% YoY); Jornay PM $28.5M (+24% Rx growth); pain portfolio $149.2M (+3%).","GAAP net income $2.4M ($0.07 diluted EPS); non-GAAP adj. net income $57.4M ($1.49 adj. EPS).","Adjusted EBITDA $95.2M (+3% YoY); cash & securities $197.8M, up from $162.8M at Dec 31, 2024.","Board authorized $25M accelerated share repurchase; paid down $16.1M in debt during Q1.","Expanded Jornay PM sales force to ~180 reps; new Chairman, board members, and execs appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":177757000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170769,"accession_number":"0001104659-25-024185","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Collegium nominates Carlos Paya; founder Heffernan retires as Chairman, Santini named; appoints David Dieter as GC","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Carlos Paya nominated for election to Board at 2025 Annual Meeting; current venture partner at Abingworth/Carlyle.","Founder and Chairman Michael Heffernan will not stand for re-election and retire from Board at Annual Meeting.","Gino Santini named Chairman of the Board effective immediately after Annual Meeting; Heffernan to serve as Chairman until then.","Director Gwen Melincoff also retiring from Board at Annual Meeting; departures part of board refreshment, not due to disagreements.","David Dieter appointed EVP and General Counsel effective March 17, 2025; previously VP Legal at Horizon Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170768,"accession_number":"0001558370-25-001799","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Collegium reports record Q4 revenue $181.9M, GAAP EPS $0.36; EVP Shirley Kuhlmann departing March 7","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $181.9M (+22% YoY); GAAP net income $12.5M ($0.36 diluted EPS); adjusted EBITDA $107.7M.","FY2024 product revenue $631.4M (+11% YoY); GAAP net income $69.2M ($1.86 diluted EPS); adjusted EBITDA $401.2M.","Jornay PM pro forma FY2024 net rev $100.7M; expects >$135M in 2025. Belbuca Q4 net rev $55.2M (+12% YoY); Xtampza ER $51.5M (+6% YoY).","Reaffirmed FY2025 guidance: product revenue $735-750M, adj EBITDA $435-450M. Repurchased $60M in shares in 2024; cash $162.8M.","EVP, Chief Admin Officer, General Counsel & Secretary Shirley Kuhlmann stepping down effective March 7, 2025; treated as termination without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":631449000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170767,"accession_number":"0001104659-25-009384","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Collegium expands board, appoints Nancy Lurker as new director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 8 to 9 directors; Nancy Lurker appointed effective Feb 4, 2025.","Lurker, 67, former CEO of EyePoint Pharmaceuticals, currently vice chair of EyePoint board.","She will receive annual cash retainer of $50,000 (prorated) and equity award of $412,500 in RSUs vesting over 1 year.","Board determined Lurker is independent under Nasdaq rules; no related party transactions.","She also serves on boards of Alkermes (ALKS), Altasciences, and National Sanitation Foundation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170766,"accession_number":"0001104659-25-001873","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Collegium provides 2025 guidance: product revenue $735M-$750M, adj EBITDA $435M-$450M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Product revenues, net expected $735M-$750M for 2025.","Jornay PM net revenue expected >$135M in 2025.","Adjusted EBITDA (excl. SBC) expected $435M-$450M.","Adjusted operating expenses (excl. SBC) expected $220M-$230M.","Repurchased $60M in shares in 2024 under $150M buyback program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187734,"accession_number":"0001104659-24-118858","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K/A","filed_at":"2024-11-14T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Collegium completes Ironshore acquisition; discloses Ironshore's $49.8M net loss for 2023 and $67.4M for H1 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Sept 3, 2024; Ironshore's JORNAY PM (ADHD) product revenue $78.6M in 2023, $43.8M in H1 2024.","Ironshore total assets $84.7M, total liabilities $442.3M, shareholders' deficit $(357.6)M at June 30, 2024.","Ironshore notes payable (current + non-current) $149.8M at June 30, 2024; asset-backed lending $12.6M.","Deferred royalty obligation $123.5M at June 30, 2024; warrant liability $8.3M; derivative liability $36.0M.","Ironshore's net loss $(49.8)M in 2023 and $(67.4)M in H1 2024, with operating losses since inception."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187735,"accession_number":"0001104659-24-115287","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Collegium posts record Q3 revenue $159.3M, up 17%; names Vikram Karnani CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $159.3M (record), up 17% YoY; GAAP net income $9.3M ($0.27 diluted EPS).","Adjusted EBITDA $105.1M, up 18% YoY; non-GAAP adjusted EPS $1.61.","Reaffirms FY2024 guidance: product revenue $620-635M, adjusted EBITDA $395-405M.","Appoints Vikram Karnani as President and CEO effective Nov 12, 2024; Heffernan remains Chairman.","Closed Ironshore acquisition (Jornay PM) in Sep 2024, entering ADHD neurology."],"consensus_eps_estimate":null,"consensus_eps_actual":1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":449500000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204239,"accession_number":"0001104659-24-096647","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["2.01","2.03","7.01","9.01"],"status":"ready","headline":"Collegium closes $525M Ironshore acquisition; adds Jornay PM, boosts 2024 outlook","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Ironshore acquired for $525M cash plus potential $25M milestone based on Jornay PM 2025 net revenue.","Jornay PM (ADHD) expected >$100M net revenue in 2024; prescriptions grew 32% YoY in H1 2024.","2024 guidance updated: product revenue $620-635M, adjusted EBITDA $395-405M, reflecting four months of Ironshore.","Financed with $200M cash and $325M draw on new $646M term loan; interest rate reduced 300 bps.","Establishes presence in neurology/ADHD; Jornay PM poised as leading growth driver; patents to 2032."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204238,"accession_number":"0001558370-24-011583","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q2 revenue up 7% to $145.3M; adjusted EPS $1.62; Ironshore acquisition on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $145.3M (+7% YoY); Belbuca record $52.2M (+21% YoY); GAAP net income $19.6M (+51% YoY).","Non-GAAP adjusted net income $64.0M, adjusted EPS $1.62; Adjusted EBITDA $96.0M (+12% YoY).","Acquiring Ironshore Therapeutics for $525M cash + up to $25M milestone; expected close Q3'24; funded by new $646M term loan.","Reaffirmed FY2024 guidance: Product Revenue $580-595M, Adjusted EBITDA $380-395M.","Pediatric exclusivity for Nucynta franchise extended to Jan 2027 (Nucynta) and Dec 2025 (Nucynta ER)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":290199000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204237,"accession_number":"0001104659-24-083126","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["1.01","2.02","2.03","5.02","7.01","9.01"],"status":"ready","headline":"Collegium to acquire Ironshore Therapeutics for $525M; Jornay PM ADHD drug; Q2 prelim rev $145M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires Ironshore for $525M cash plus up to $25M milestone if Jornay PM net revenue exceeds defined 2025 threshold.","Jornay PM (ADHD) expected >$100M net revenue in 2024; H1 2024 prescriptions up 32% YoY.","Funded by cash on hand and new $646M five-year Pharmakon loan with 300bps rate reduction.","Preliminary Q2 2024 net product revenue $145M (+7% YoY); reaffirms FY2024 guidance of $580-595M revenue, $380-395M adj EBITDA.","Director Neil McFarlane resigned immediately due to conflict of interest (CEO of Zevra Therapeutics)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220970,"accession_number":"0001104659-24-071070","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants pediatric exclusivity for Nucynta franchise; exclusivity extended to Jan 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted pediatric exclusivity for Nucynta and Nucynta ER; Nucynta exclusivity now to Jan 3, 2027, Nucynta ER to Dec 27, 2025.","Pediatric exclusivity adds six months on top of previously granted New Patient Population exclusivity (granted 2023).","Collegium CMO Thomas Smith said the grant enhances the value of the Nucynta franchise and bolsters near-term outlook.","Nucynta is approved for acute pain in adults and pediatric patients 6+; Nucynta ER for severe pain and diabetic peripheral neuropathy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220969,"accession_number":"0001104659-24-065119","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Collegium appoints Michael Heffernan interim CEO with base salary $291,666; Ciaffoni separation agreed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Heffernan appointed Interim President and CEO effective May 24, 2024; annual base salary $291,666 (one-third of prior CEO).","Heffernan's employment is at-will; Board may terminate at any time or extend by mutual agreement.","Separation and Release Agreement with departing CEO Joseph Ciaffoni grants severance per employment agreement for termination without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220968,"accession_number":"0001104659-24-063396","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Collegium shareholders re-elect all eight directors and approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees re-elected; each received >98% of votes cast (For range: 25.4M-28.4M).","Advisory vote on executive compensation passed with 28,311,783 For (98.8% of votes cast).","Ratification of Deloitte & Touche as independent auditor for FY2024 approved with 30,106,217 For.","Annual meeting held May 16, 2024; 31,059,529 shares present (94.9% of outstanding shares).","Broker non-votes were 2,360,841 on director and say-on-pay; 837,061 on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220967,"accession_number":"0001104659-24-060235","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Collegium executes $35M accelerated share repurchase with Jefferies; initial 888,889 shares delivered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ASR agreement under $150M buyback program authorized in Jan 2024; $35M paid to Jefferies.","Initial delivery of 888,889 shares based on $31.50 closing price on May 10, 2024 (~80% of expected total).","Final number determined by VWAP during ASR term; settlement expected Q3 2024.","As of March 31, 2024, outstanding shares ~32.7M, implying initial delivery covers ~2.7% of shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220966,"accession_number":"0001104659-24-059656","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO Joseph Ciaffoni steps down; Chairman Michael Heffernan named Interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Ciaffoni to step down as President and CEO effective May 24, 2024.","Ciaffoni will not stand for re-election to the Board at May 16 Annual Meeting; Board reduced from nine to eight.","Michael Heffernan, current Chairman, appointed Interim President and CEO effective May 24, 2024.","Heffernan to receive base salary at $291,666 annual rate (one-third of Ciaffoni's salary).","Board has initiated a search for a permanent President and CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220965,"accession_number":"0001558370-24-007596","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q1 net revenue $144.9M, GAAP net income $27.7M, CEO steps down May 24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income of $27.7M ($0.71 diluted EPS) vs. loss of $(17.4M) in Q1 2023.","Adjusted EBITDA of $92.4M, up 5% YoY; non-GAAP adjusted EPS of $1.45.","Record Belbuca revenue of $50.7M, up 15% YoY; total prescriptions up 4.2%.","CEO Joe Ciaffoni to step down May 24, 2024; Michael Heffernan named interim CEO.","Board authorized $35M accelerated share repurchase program; reiterated FY2024 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":144923000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220964,"accession_number":"0001104659-24-053506","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Collegium enters authorized generic agreement with Hikma for Nucynta IR and ER","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hikma gains exclusive US marketing rights for authorized generics of Nucynta IR and ER; launch 30 days before LOE.","Collegium receives profit share starting in mid-80% range, declining based on third-party generic equivalents entering.","Collegium will supply Nucynta AG products at fully burdened manufacturing cost; Hikma purchases exclusively from Collegium.","Hikma cannot market its own generic equivalents of Nucynta while marketing the authorized generics.","Initial term 5 years with auto-renewal; termination for material breach or bankruptcy; Hikma may terminate with 1-year notice after first anniversary of launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220963,"accession_number":"0001104659-24-046091","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Collegium calls all $26.35M of 2.625% Convertible Notes due 2026 for redemption June 14","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Called all $26,350,000 of outstanding 2.625% Convertible Senior Notes due 2026; redemption date June 14, 2024.","Redemption price: 100% of principal plus accrued interest, approximately $1,008.68 per $1,000 note.","Triggered by common stock price exceeding 130% of conversion price for required period under indenture.","Conversion rate increased to 36.7815 shares per $1,000 principal due to Make-Whole Fundamental Change; conversions settled in cash.","Interest ceases after Redemption Date unless company defaults; holders must surrender notes by June 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240561,"accession_number":"0001558370-24-001524","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Pharma reports record Q4/FY2023 revenue; GAAP net income of $31.9M Q4, $48.2M FY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 revenue $149.7M (+16% YoY); FY revenue $566.8M (+22% YoY).","GAAP net income $31.9M Q4 ($0.82 diluted) vs loss of $7.2M in Q4 2022; FY net income $48.2M.","Record adjusted EBITDA $104.2M Q4, $367.0M FY (+38% YoY each).","Repurchased $75M shares in 2023; new $150M buyback authorized Jan 2024.","FY 2024 guidance: product revenue $580–595M, adjusted EBITDA $380–395M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":566767000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240560,"accession_number":"0001104659-24-000579","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Collegium 2024 guidance: revenue $580-595M, adj. EBITDA $380-395M, $150M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 product revenue net expected $580M-$595M; adjusted EBITDA $380M-$395M.","Board authorized $150M share repurchase program through June 30, 2025.","Xtampza ER gross-to-net improving to 56%-58% after renegotiations covering 30% of scripts.","Belbuca renegotiated major Medicare Part D contract, reducing rebate, and won new plan (~1M lives).","Returned $75M to shareholders in 2023 under prior buyback, including $25M accelerated repurchase."],"consensus_eps_estimate":null,"consensus_eps_actual":1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":566767000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258065,"accession_number":"0001104659-23-116013","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Collegium executes $25M accelerated share repurchase; initial delivery of 865K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Executed ASR with Jefferies LLC to repurchase $25M of Collegium common stock.","Initial delivery of ~865,426 shares based on $23.11 closing price (Nov 8, 2023), ~80% of expected total.","Final settlement expected in Q4 2023; shares outstanding ~33.1M as of Sep 30, 2023.","Part of $100M share repurchase program authorized by Board in January 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258064,"accession_number":"0001558370-23-017980","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q3 revenue $136.7M (+8% YoY), adj. EBITDA record $89.4M, guidance tightened","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $20.6M vs $0.5M; diluted EPS $0.53; adjusted EPS $1.34.","Belbuca net revenue $45.4M (+17% YoY); Xtampza ER $39.8M; Nucynta franchise $47.5M.","Updated FY23 guidance: revenue $565-570M, adj. EBITDA $360-365M, op. expenses $125-130M.","Nucynta exclusivity extended to July 2026; board authorized $25M ASR program.","Cash and securities $304.6M, up from $173.7M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":417022000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275377,"accession_number":"0001104659-23-094746","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-08-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Nucynta IR exclusivity extension to July 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted New Patient Population exclusivity for Nucynta (tapentadol IR), extending U.S. exclusivity from June 27, 2025 to July 3, 2026.","Extension based on pediatric trial data submitted per FDA Pediatric Written Request for pain treatment in patients aged 6+.","Collegium continues pursuit of pediatric extension for entire Nucynta Franchise, which could add six months for Nucynta ER and IR.","Nucynta is approved for acute pain severe enough to require an opioid analgesic in adults and pediatric patients weighing ≥40 kg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275376,"accession_number":"0001104659-23-088079","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Collegium enters $50M accelerated share repurchase under $100M buyback program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$50 million ASR agreement with Jefferies LLC; initial delivery of ~1.7M shares (80% of expected) based on $23.49 close","Final settlement expected in Q4 2023 based on volume-weighted average price during term","Part of $100M share repurchase program authorized by Board in January 2023","As of June 30, 2023, approximately 34.7 million shares outstanding"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275375,"accession_number":"0001558370-23-013191","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q2 net revenue $135.5M (+10% YoY); GAAP net income $13.0M vs loss; authorizes $50M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 GAAP net income $13.0M ($0.34 diluted EPS) vs GAAP net loss of $5.2M a year ago; adjusted EBITDA $85.8M, up 21% YoY.","Board authorized $50M accelerated share repurchase program; reaffirmed FY2023 guidance product revenue $565-580M, adjusted EBITDA $355-370M.","Xtampza ER revenue grew 24% YoY to $41.2M; Nucynta franchise revenue up 8% YoY to $47.3M; Belbuca prescriptions up 3.5% QoQ.","FDA approved Nucynta for children ages 6+; pediatric extension could extend exclusivity to Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":280313000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292857,"accession_number":"0001104659-23-062681","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Collegium shareholders elect all nine directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees re-elected; votes ranged from 25.9M to 28.3M for, with broker non-votes of ~2.46M.","Advisory say-on-pay approved with 27,953,926 for, 315,383 against, 90,502 abstentions.","Ratification of Deloitte & Touche as independent auditor for FY2023 passed with 30,742,534 for, 44,006 against, 29,155 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292856,"accession_number":"0001558370-23-008080","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium reports record Q1 revenue $144.8M, adjusted EPS $1.32, reaffirms FY23 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record product revenue net of $144.8M, up 73% YoY from $83.8M.","Non-GAAP adjusted net income $51.7M with adjusted EPS $1.32 vs $0.71 YoY.","Adjusted EBITDA $87.6M, up 101% YoY from $43.5M.","Cash balance $269.5M; completed $241.5M convertible note offering due 2029.","Reaffirmed FY23 product revenue $565-580M and adjusted EBITDA $355-370M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":144767000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313519,"accession_number":"0001558370-23-001897","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q4 record net revenue $129.6M; FY22 adj. EBITDA $266.0M, reaffirms 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $129.6M (up from $27.4M YoY); GAAP net loss $(7.2)M vs $(25.0)M YoY.","FY22 product revenue $463.9M (up 68% YoY); non-GAAP adjusted EPS $3.96 vs $2.58.","Completed BDSI integration with $85M run-rate synergies; resolved all 27 opioid lawsuits.","Board authorized $100M share repurchase program in Jan 2023; cash balance $173.7M at year-end.","Reaffirms 2023 guidance: product revenue $565-580M, adjusted EBITDA $355-370M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":463933000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313518,"accession_number":"0001104659-23-019671","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Collegium prices $241.5M convertible notes offering, repurchases $117.4M of 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $210M convertible notes offering, upsized to $241.5M with full exercise of initial purchasers' option.","Notes bear 2.875% interest, mature Feb 2029; initial conversion price $36.56/share, ~30% premium to $28.12.","Net proceeds estimated at $203.2M ($233.8M if greenshoe fully exercised) after discounts and expenses.","Used $140.1M to repurchase $117.4M of its 2.625% convertible notes due 2026.","Remainder for general corporate purposes including business development and capital allocation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313517,"accession_number":"0001104659-23-011184","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Collegium prelim Q4/FY22 revenue at high-end of guidance; announces $175M convertible notes offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Prelim FY22 product revenue $460.0M-$462.5M; Q4 $125.7M-$128.2M; both at or above prior guidance high-end.","Prelim FY22 adjusted EBITDA $261.5M-$264.0M; Q4 adjusted EBITDA $71.9M-$74.4M.","Announced $175M convertible senior notes due 2029, with $26.25M greenshoe option to initial purchaser.","Intends to use part of proceeds to repurchase portion of its 2.625% 2026 convertible notes in private transactions.","Remaining proceeds for general corporate purposes including business development, debt repayment, and shareholder returns."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":463933000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313516,"accession_number":"0001104659-23-000644","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Collegium provides 2023 guidance: rev $565-580M, adj EBITDA $355-370M, $100M buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Product revenue net expected $565-580M for 2023, up from ~$460M in 2022.","Adjusted EBITDA $355-370M, growing >4x rate of adjusted operating expenses ($135-145M).","Board authorized $100M share repurchase program through December 31, 2023.","Xtampza ER gross-to-net expected 61-63% in 2023, down from >65% previously.","Federal Circuit upheld Belbuca patents, blocking Alvogen generic entry until 2032."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332000,"accession_number":"0001104659-22-129343","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Federal Circuit upholds Collegium's Belbuca patents; blocks Alvogen generic until 2032","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Alvogen conceded infringement; Federal Circuit ruling bars generic entry until 2032 patent expiry (9,901,539 patent).","Court upheld validity of claims in '866 (2027) and '539 (2032) patents; remanded some claims of '866 and '843 patents (2027) for reconsideration.","Decision reinforces strength of Belbuca patent portfolio, protecting key chronic pain product from generic competition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331999,"accession_number":"0001558370-22-016231","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q3 record revenue $127M (+61% YoY), adj. EPS $1.10, raises FY guidance; completes Xtampza ER renegotiation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q3 revenue $127.0M (+61% YoY); GAAP net income $0.5M ($0.01 EPS), adj. net income $42.5M ($1.10 adj. EPS).","Completed Xtampza ER contract renegotiations; gross-to-net <65% effective Jan 1, 2023, maintaining broad access.","Returned $10M capital via share repurchases ($6.4M in Q3, $3.6M in Oct). $42.1M remains under $100M program.","Updated FY2022 guidance: revenue $455-465M, adj. EBITDA $250-255M, adj. opex $125-130M.","Ended Q3 with $134.1M cash; made $25M debt repayments; BDSI synergy target raised to ~$85M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":334313000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349463,"accession_number":"0001558370-22-012165","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Collegium Q2 revenue $123.5M record, raises FY Adj EBITDA guidance to $245-255M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net product revenue $123.5M (record), up from $82.9M YoY.","GAAP net loss $5.2M ($0.15 loss per share) vs $72.8M income in prior year (included tax benefit).","Adjusted EBITDA $71.2M, up from $40.1M YoY; full-year Adj EBITDA guidance raised to $245-255M.","BDSI integration complete; on track to exceed targeted run-rate synergies of at least $75M.","Opioid lawsuits resolved via master settlement agreement covering 27 pending cases."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":207300000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366411,"accession_number":"0001104659-22-063841","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders re-elect six directors, approve say-on-pay, and ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees re-elected (avg. ~29M for, ~0.8M against).","Advisory say-on-pay vote approved with 28.3M for, 0.64M against.","Ratification of Deloitte & Touche as auditor for FY2022 approved with 31.2M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366406,"accession_number":"0001104659-22-060286","cik":1267565,"company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","form_type":"8-K/A","filed_at":"2022-05-13T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Collegium files BDSI acquisition pro forma; $669M total consideration, $75M annual synergy target","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration for BDSI acquisition: $669.4M ($606.4M cash to stockholders at $5.60/share + $63.0M to retire BDSI debt).","Pro forma combined 2021 revenue $443.6M, net income $23.5M after $132.9M in transaction-related adjustments.","Company expects at least $75M in annual run-rate cost synergies within 12 months of closing (headcount reductions and consolidation).","Acquisition financed via a new $650.0M term loan (modification of existing Collegium term loan); BDSI term loan paid at close.","Preliminary purchase price allocation includes $445M in identifiable intangible assets (Belbuca, Symproic, Elyxyb) and $134M in goodwill."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1104370241.9581354,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-13T23:59:59+00:00|366406"}